Back to Search Start Over

Characterization of T and B cell epitopes in PvCyRPA by studying the naturally acquired immune response in Brazilian Amazon communities.

Authors :
Soares IF
de Oliveira Baptista B
da Silva Matos A
Rodrigues-da-Silva RN
Kujbida Junior MA
Albrecht L
Rodolphi CM
Scopel KKG
Alencar ALC
de Souza RM
Dos Santos de Souza HA
Riccio EKP
de Barros JP
Totino PRR
Daniel-Ribeiro CT
Pratt-Riccio LR
Lima-Junior JDC
Source :
Scientific reports [Sci Rep] 2024 Nov 09; Vol. 14 (1), pp. 27343. Date of Electronic Publication: 2024 Nov 09.
Publication Year :
2024

Abstract

Plasmodium vivax, a challenging species to eliminate, causes millions of malaria cases globally annually. Developing an effective vaccine is crucial in the fight against vivax malaria, but considering the limited number of studies focusing on the identification and development of P. vivax-specific vaccine candidates, exploring new antigens is an urgent need. The merozoite protein CyRPA is essential for P. falciparum growth and erythrocyte invasion and corresponds to a promising candidate antigen. In P. vivax, a single study with multiple vaccine candidates indicates PvCyRPA with strong association with protection, outperforming classic malaria vaccine candidates. However, little is known about the specific naturally acquired response in the Americas, as well as the antigen epitope mapping. For this reason, we aimed to investigate the cellular and humoral immune response elicited against PvCyRPA in Brazilian endemic areas to identify the existence of immunodominant regions and the potential of this protein as a single or even a multi-stage specific malaria vaccine candidate for P. vivax. The results demonstrated that PvCyRPA is naturally immunogenic in Brazilian Amazon individuals previously exposed to malaria, which presented anti-PvCyRPA cytophilic antibodies. Moreover, our data show that the protein also possesses important immunogenic regions with an overlap of B and T cell epitopes. These data reinforce the possibility of including PvCyRPA in vaccine formulations for P. vivax.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
2045-2322
Volume :
14
Issue :
1
Database :
MEDLINE
Journal :
Scientific reports
Publication Type :
Academic Journal
Accession number :
39521783
Full Text :
https://doi.org/10.1038/s41598-024-72671-x